As such, supports use of TF-targeted therapeutics in clinical trials of several angiogenesis-dependent common human diseases, notably cancer, macular degeneration, endometriosis and rheumatoid arthritis, in which VEGF plays a central role in pathological angiogenesis. Here, TF is linked to macular degeneration.